Numab Therapeutics AG: Numab and 3SBio's Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option

Related Keywords

Taiwan ,Shanghai ,China ,Hong Kong ,Shenzhen ,Guangdong ,Shenyang ,Liaoning ,Italy ,Zurich ,Züsz ,Switzerland ,Guojian ,Jing Lou ,Hangzhou ,Zhejiang ,Macao ,Macau General ,Macau ,David Urech ,Madeline Davidshofer ,Sunshine Guojian Pharmaceutical Shanghai Co Ltd ,3sbio Inc , ,Numab Therapeutics ,Sunshine Guojian Pharmaceutical ,Sunshine Guojian ,Greater China ,Chief Executive Officer ,Serum Albumin ,Executive Officer ,Dougall Advisors ,Numab ,Herapeutics ,Lsbio ,Sunshine ,Xpand ,Partnership ,Evelop ,Novel ,Fell ,Engager ,M28 ,